S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.49 (-0.26%)
AAPL   149.09 (+0.22%)
MSFT   307.43 (-0.26%)
FB   340.60 (+0.18%)
GOOGL   2,831.05 (-1.18%)
TSLA   857.47 (-0.79%)
AMZN   3,411.10 (-0.96%)
NVDA   221.03 (-0.84%)
BABA   177.37 (+0.21%)
NIO   39.56 (-1.17%)
CGC   14.25 (-0.63%)
GE   105.95 (+1.16%)
AMD   116.44 (+0.09%)
MU   68.28 (+1.05%)
T   25.89 (+1.17%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.10 (-0.63%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.88 (+0.20%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.49 (-0.26%)
AAPL   149.09 (+0.22%)
MSFT   307.43 (-0.26%)
FB   340.60 (+0.18%)
GOOGL   2,831.05 (-1.18%)
TSLA   857.47 (-0.79%)
AMZN   3,411.10 (-0.96%)
NVDA   221.03 (-0.84%)
BABA   177.37 (+0.21%)
NIO   39.56 (-1.17%)
CGC   14.25 (-0.63%)
GE   105.95 (+1.16%)
AMD   116.44 (+0.09%)
MU   68.28 (+1.05%)
T   25.89 (+1.17%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.10 (-0.63%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.88 (+0.20%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.49 (-0.26%)
AAPL   149.09 (+0.22%)
MSFT   307.43 (-0.26%)
FB   340.60 (+0.18%)
GOOGL   2,831.05 (-1.18%)
TSLA   857.47 (-0.79%)
AMZN   3,411.10 (-0.96%)
NVDA   221.03 (-0.84%)
BABA   177.37 (+0.21%)
NIO   39.56 (-1.17%)
CGC   14.25 (-0.63%)
GE   105.95 (+1.16%)
AMD   116.44 (+0.09%)
MU   68.28 (+1.05%)
T   25.89 (+1.17%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.10 (-0.63%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.88 (+0.20%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.49 (-0.26%)
AAPL   149.09 (+0.22%)
MSFT   307.43 (-0.26%)
FB   340.60 (+0.18%)
GOOGL   2,831.05 (-1.18%)
TSLA   857.47 (-0.79%)
AMZN   3,411.10 (-0.96%)
NVDA   221.03 (-0.84%)
BABA   177.37 (+0.21%)
NIO   39.56 (-1.17%)
CGC   14.25 (-0.63%)
GE   105.95 (+1.16%)
AMD   116.44 (+0.09%)
MU   68.28 (+1.05%)
T   25.89 (+1.17%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.10 (-0.63%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.88 (+0.20%)
NASDAQ:SESN

Sesen Bio Stock Forecast, Price & News

$1.26
+0.25 (+24.75 %)
(As of 10/20/2021 04:13 PM ET)
Add
Compare
Today's Range
$1.08
$1.47
50-Day Range
$0.73
$4.91
52-Week Range
$0.70
$6.04
Volume4.50 million shs
Average Volume11.26 million shs
Market Capitalization$246.96 million
P/E RatioN/A
Dividend YieldN/A
Beta0.5
30 days | 90 days | 365 days | Advanced Chart
Receive SESN News and Ratings via Email

Sign-up to receive the latest news and ratings for Sesen Bio and its competitors with MarketBeat's FREE daily newsletter.


Sesen Bio logo

About Sesen Bio

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Headlines

Sesen Bio Target of Unusually Large Options Trading (NASDAQ:SESN)
October 20, 2021 |  americanbankingnews.com
SESEN DEADLINE ALERT: Faruqi & Faruqi LLP...
October 17, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SESN
Employees
27
Year Founded
N/A

Sales & Book Value

Annual Sales
$11.24 million
Book Value
($0.07) per share

Profitability

Net Income
$-22.40 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$246.96 million
Next Earnings Date
11/8/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

1.56 out of 5 stars

Medical Sector

1015th out of 1,360 stocks

Pharmaceutical Preparations Industry

491st out of 667 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Sesen Bio (NASDAQ:SESN) Frequently Asked Questions

Is Sesen Bio a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sesen Bio in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Sesen Bio stock.
View analyst ratings for Sesen Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Sesen Bio?

Wall Street analysts have given Sesen Bio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sesen Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Sesen Bio?

Sesen Bio saw a drop in short interest in the month of September. As of September 30th, there was short interest totaling 7,660,000 shares, a drop of 49.6% from the September 15th total of 15,200,000 shares. Based on an average daily trading volume, of 19,810,000 shares, the short-interest ratio is presently 0.4 days.
View Sesen Bio's Short Interest
.

When is Sesen Bio's next earnings date?

Sesen Bio is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Sesen Bio
.

How were Sesen Bio's earnings last quarter?

Sesen Bio, Inc. (NASDAQ:SESN) announced its quarterly earnings data on Sunday, August, 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.09. The business had revenue of $2.23 million for the quarter, compared to analysts' expectations of $2.40 million.
View Sesen Bio's earnings history
.

How has Sesen Bio's stock been impacted by Coronavirus (COVID-19)?

Sesen Bio's stock was trading at $0.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SESN shares have increased by 87.5% and is now trading at $1.35.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SESN?

2 Wall Street analysts have issued 12 month price targets for Sesen Bio's shares. Their forecasts range from $3.00 to $8.00. On average, they expect Sesen Bio's share price to reach $5.50 in the next year. This suggests a possible upside of 307.4% from the stock's current price.
View analysts' price targets for Sesen Bio
or view top-rated stocks among Wall Street analysts.

Who are Sesen Bio's key executives?

Sesen Bio's management team includes the following people:
  • Thomas R. Cannell, President, Chief Executive Officer & Director
  • Monica Forbes, Chief Financial Officer & Treasurer
  • Jeannick Cizeau, Head of Research
  • Glen C. MacDonald, Chief Technology Officer
  • Dewey McLin, Vice President-Medical Affairs

What other stocks do shareholders of Sesen Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include Amarin (AMRN), XOMA (XOMA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Verastem (VSTM), Sorrento Therapeutics (SRNE), Novavax (NVAX), Biocept (BIOC), Micron Technology (MU) and OPKO Health (OPK).

What is Sesen Bio's stock symbol?

Sesen Bio trades on the NASDAQ under the ticker symbol "SESN."

Who are Sesen Bio's major shareholders?

Sesen Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Stratos Wealth Partners LTD. (0.20%) and XR Securities LLC (0.00%).

Which major investors are buying Sesen Bio stock?

SESN stock was purchased by a variety of institutional investors in the last quarter, including Stratos Wealth Partners LTD., and XR Securities LLC.

How do I buy shares of Sesen Bio?

Shares of SESN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sesen Bio's stock price today?

One share of SESN stock can currently be purchased for approximately $1.35.

How much money does Sesen Bio make?

Sesen Bio has a market capitalization of $264.60 million and generates $11.24 million in revenue each year. The company earns $-22.40 million in net income (profit) each year or ($0.15) on an earnings per share basis.

How many employees does Sesen Bio have?

Sesen Bio employs 27 workers across the globe.

What is Sesen Bio's official website?

The official website for Sesen Bio is www.sesenbio.com.

Where are Sesen Bio's headquarters?

Sesen Bio is headquartered at 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142.

How can I contact Sesen Bio?

Sesen Bio's mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The company can be reached via phone at (617) 444-8550 or via email at [email protected].


This page was last updated on 10/20/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.